BRL-101 for severe sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new treatment called BRL-101 for people with severe sickle cell disease. The treatment uses your own stem cells, which are modified in the lab and then given back to you. It aims to reduce pain crises and improve your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 35 years old.
- You have severe sickle cell disease (types like HbSS, HbSβ0, or HbSβ+).
- You have had at least 2 pain crises each year for the past 2 years.
- You are healthy enough for a stem cell transplant using your own cells.
- You have not had a stem cell transplant, gene therapy, or gene editing before.
- You do not have a matched brother or sister who can donate stem cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests a gene therapy that uses a modified virus to deliver a healthy gene to your blood stem cells. It aims to help people with sickle cell disease produce normal red blood cells and reduce painful crises.
This trial tests a new gene therapy called KL003 for people with severe sickle cell disease. It aims to fix your own stem cells so they make healthy red blood cells, reducing pain crises. You may qualify if you've had at least four severe pain episodes in the last two years and have not responded well to hydroxyurea.
This trial tests a high-dose medicine to collect stem cells from young adults with sickle cell disease. It aims to prepare for a transplant that could potentially cure the condition.
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.